Published doctor content from the Docuniv editorial system, organized for mobile reading and quick clinical review.
Type 2 diabetes is silent for years. Opportunistic screening, prompt confirmation and early intensive management in primary care reduce long-term complications and, for some, ca...
SUSTAIN (injectable) and PIONEER (oral) programmes established semaglutide as a potent glucose- and weight-lowering agent with cardiovascular safety, and cardiovascular benefit ...
SURMOUNT-5, the first randomised head-to-head trial in obesity, showed greater weight loss with tirzepatide than semaglutide over 72 weeks. Earlier diabetes data (SURPASS-2) poi...
FLOW showed that once-weekly semaglutide 1.0 mg reduced major kidney events by 24% in people with type 2 diabetes and chronic kidney disease (CKD), on top of standard care. It w...
GLP-1 receptor agonists are generally well tolerated, but concerns regarding diabetic retinopathy, optic neuropathy, psychiatric effects and aspiration risk during anaesthesia w...
Type a question about medicines, diet, symptoms, cases, algorithms, guidelines, or conference updates.